跳至主要内容
临床试验/EUCTR2011-003825-81-ES
EUCTR2011-003825-81-ES进行中(未招募)1 期

A Multicenter, Open-Label, Non-Randomized Study to Assess the Pharmacokinetics, Tolerability, and Safety of a Single Subcutaneous Administration of Icatibant in Children and Adolescents with Hereditary Angioedema

Shire Orphan Therapies, Inc0 个研究点目标入组 36 人开始时间: 2011年11月21日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
36

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • 1. Two through 17 years of age, inclusive (ie, from the second birthday until the day prior to the eighteenth birthday) at the time of the subjects first attack.
  • 2. Documented diagnosis of HAE Type I or II. Diagnosis must be confirmed by documented immunogenic and/or functional C1-INH deficiency results (<50% of normal levels). Diagnosis may be on the basis of historic data or by diagnostic testing conducted at the time of screening.
  • 3. Informed consent (and subject assent as appropriate) signed by the subjects parent(s) or legal guardian(s).
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range: 36
  • F.1.2 Adults (18-64 years) no
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • 1. Diagnosis of angioedema other than HAE.
  • 2. Participation in another clinical study during the 30 days prior to treatment.
  • 3. Any known factor/disease that might interfere with the treatment compliance, study conduct or result interpretation.
  • 4. Congenital or acquired cardiac anomalies that interfere significantly with cardiac function.
  • 5. Treatment with ACE inhibitors within 7 days prior to treatment.
  • 6. Use of hormonal contraception within the 90 days prior to treatment.
  • 7. Androgen use (eg, stanozolol, danazol, oxandrolone, methyltestosterone, testosterone) within the 90 days prior to treatment.
  • 8. The subject is pregnant or breastfeeding.

研究者

发起方
Shire Orphan Therapies, Inc

相似试验

进行中(未招募)
1 期
A clinical study intended to measure in the bodies of children and adolescents how drug Icatibant is absorbed and removed after a single administration (dose). The children and adolescents in the study will all have the disease called Hereditary Angioedema (which causes abnormal swelling of the body), this is because the drug icatibant is intended to treat Hereditary Angiodema. The study will also look for side effects that may be due to the drugMedDRA version: 16.0Level: PTClassification code 10019860Term: Hereditary angioedemaSystem Organ Class: 10010331 - Congenital, familial and genetic disordersHereditary Angioedema
EUCTR2011-003825-81-DEShire Orphan Therapies, Inc36
进行中(未招募)
不适用
A clinical study intended to measure in the bodies of children and adolescents how drug Icatibant is absorbed and removed after a single administration (dose). The children and adolescents in the study will all have the disease called Hereditary Angiodema this is because the drug icatibant is intended to treat Hereditary Angiodema. The study will also look for side effects that may be due to the drugMedDRA version: 14.1Level: PTClassification code 10019860Term: Hereditary angioedemaSystem Organ Class: 10010331 - Congenital, familial and genetic disordersHereditary Angioedema
EUCTR2011-003825-81-ITSHIRE HUMAN GENETIC THERAPIES, INC.36
进行中(未招募)
1 期
A clinical study intended to measure in the bodies of children and adolescents how drug Icatibant is absorbed and removed after a single administration (dose). The children and adolescents in the study will all have the disease called Hereditary Angioedema (which causes abnormal swelling of the body), this is because the drug icatibant is intended to treat Hereditary Angiodema. The study will also look for side effects that may be due to the drugMedDRA version: 19.0Level: PTClassification code 10019860Term: Hereditary angioedemaSystem Organ Class: 10010331 - Congenital, familial and genetic disordersHereditary Angioedema
EUCTR2011-003825-81-ATShire Orphan Therapies, LLC32
进行中(未招募)
1 期
A clinical study intended to measure in the bodies of children and adolescents how drug Icatibant is absorbed and removed after a single administration (dose). The children and adolescents in the study will all have the disease called Hereditary Angioedema (which causes abnormal swelling of the body), this is because the drug icatibant is intended to treat Hereditary Angiodema. The study will also look for side effects that may be due to the drugMedDRA version: 23.1Level: PTClassification code 10019860Term: Hereditary angioedemaSystem Organ Class: 10010331 - Congenital, familial and genetic disordersHereditary Angioedema
EUCTR2011-003825-81-HUShire Orphan Therapies, Inc32
进行中(未招募)
1 期
A study to evaluate the efficacy and safety of ibrutinib and ofatumumab in untreated patients with chronic lymphocytic leukemia or small cell lymphocytic lymphoma.
EUCTR2016-004937-26-ESFundación PETHEMA